Institut National De La Sante Et De La Recherche Medicale

Universitè De Montpellier

Institut Regional Du Cancer De Montpellier-val D'aurelle

Oribase Pharma

Centre National De La Recherche Scientifique

Université´ D'aix-marseille

Roche Diagnostic Systems, Inc.

Institut Regional Du Cancer De Montpellier

Biomunex Pharmaceuticals

Gamamabs Pharma Sa

Institut Paoli Calmettes

Institut Regional Du Cancer De Montpellier (icm)

Centre Val D'aurelle—paul Lamarque

Inserm

Andre Pelegrin

Christel Larbouret

Thierry Chardes

Bruno Robert

Bénédicte Fauvel

Nadège Gaborit

Christian Larroque

Wilhem Leconet

Yassamine Lazrek

Aziz Yasri

Gwenael Cheve

Daniel Baty

Jean-Marc Barret

Philippe Mondon

Isabelle Teulon

Jean-luc Teillaud

Abdelhakim Kharrat

Khalil Bouayadi

Martine Mansais

Jean-Pierre Mach

Olivier Dubreuil

Olivier Leger

Ghislaine Behar

Nadege A Gaborit

Martine Chartier

Alexey Terskikh

Pierre-emmanuel Gerard

Eugene Zhukovsky

Jean-Francois Prost

Stephane Degove

Jean-Luc Teillaud

The present disclosure relates to bispecific antibodies targeting EGFR and HER2, and methods for the production of these antibodies. The bispecific antibodies consist of one complete antibody on which two VH-VL chains are attached via a linker to each NH terminal region of both VH chains of the antibody. The bispecific antibodies constructed use the amino acid sequences of the heavy chain (VH) and the light chain (VL) variable regions of two monoclonal antibodies targeting EGFR and HER2, namely cetuximab and trastuzumab, respectively.

Bispecific antibodies targeting EGFR and HER2

The invention concerns antibody formats comprising VH sequence of Camelidae, such as llamas; antibodies of various formats have anti-CEA or anti-CD16 VH sequences thereof; vectors expressing the antibody formats, and methods for producing the same.

Production of antibody formats and immunological applications of said formats

The present disclosure relates to neuregulin (NRG)-non competitive allosteric anti-human-HER3 antibodies and uses thereof in diagnostic and therapeutic methods.

Neuregulin allosteric anti-HER3 antibody

The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9 and SEQ ID NO: 10.

Anti-Axl antibodies and uses thereof

The invention relates to antibodies against HER3 and their use in the treatment of cancer.

Antibodies against HER3

The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11.

The present invention provides for isolated anti-human-HER3 antibodies or fragments thereof. More particularly the present invention provides an isolated monoclonal antibody that specifically binds to the extracellular domain of HER-3 and competes for binding to the extracellular domain of human HER-3 with the antibody produced obtainable from hybridoma deposited as CNCM-I-4486. The antibodies described in the present invention are useful for the treatment of cancer.

Anti-human HER3 antibodies and uses thereof

The present invention provides recombinant CEA glycoproteins and methods for their production. These recombinant CEA glycoproteins s lack the C-terminal 26 amino acids which are present in natural CEA and are characterized in that they are free from cross-reactive CEA-like antigens, antigenically indistingiushable from the soluble form of CEA shed from tumor cells, and devoid of the ethanolamine which is present at the C-terminus of natural CEA, and also devoid of the additional amino acids which may be attached to the natural CEA through said ethanolamine. Said recombinant CEA glycoproteins s preferably have the amino acid sequence SEQ ID NO: 1. The CEA glycoproteins s of the invention may be used as reagents in an immunoassay for the diagnosis of neoplastic diseases. The invention also relates to a DNA encoding said recombinant CEA glycoprotein, such as the DNA having the nucleotide sequence SEQ ID NO: 2 or a functional equivalent sequence thereof. The present invention also relates to recombinant vectors comprising said DNA, which recombinant vector is capable of directing the expression of said DNA in a compatible host cell, and to transformed host cells containing such a recombinant vector. The recombinant CEA glycoprotein of the present invention, preferably integrated in a test-kit, may be used for determining the presence of tumor cells in a sample of body fluid.

Carcino-embryonic antigen derivatives lacking the carboxyl terminal end

Growing community of inventors

Montpellier, France

Andre Pelegrin